Browse by Clinical Topic:

Featured CME/CE Content:
neuroscienceCME Editors' Picks:

Perspectives in Major Depressive Disorder

neuroscienceCME Multimedia Snack

Premiere Date: Wednesday, November 5, 2014

This activity offers CE credit for:

  1. Physicians (CME)
  2. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Creditâ„¢

Credit Expiration Date:
Thursday, November 5, 2015
Note: Credit Is No Longer Available


David C. Steffens, MD, MHSDavid C. Steffens, MD, MHS 
Professor and Chair
Department of Psychiatry
University of Connecticut Health Center
Farmington, CT

Charles B. Nemeroff, MD, PhDCharles B. Nemeroff, MD, PhD 
Professor and Chair
Department of Psychiatry
Mulva Clinic for the Neurosciences
Director, Institute of Early Life Adversity Research
Dell Medical School
The University of Texas at Austin
Austin, TX

Statement of Need

Major depressive disorder (MDD) is now the second leading cause of disability worldwide and a major contributor to the health care burden, new data indicate.1 Establishing an effective treatment remains an outstanding need: up to 70% of patients with MDD do not reach remission with an adequate course of an antidepressant, and they also experience poorer long-term outcomes.2

This neuroscienceCME Snack on MDD offers new perspectives on treating this pervasive disorder and highlights residual symptoms as a challenge to clinicians.

  1. Ferrari AJ, Charlson FJ, Norman RE, et al. The epidemiological modelling of major depressive disorder: application for the Global Burden of Disease Study 2010. PLoS One. 2013;8(7):e69637. PMID: 23922765.
  2. Trivedi MH, Rush AJ, Wisniewski SR, et al; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40. PMID: 16390886.

Activity Goal

This educational activity centers on the CME Outfitters Make One Change statement. This statement is crafted from pertinent quality measures or clinical guidelines as a performance challenge to all participants. The Make One Change statement for this activity is:

Regularly use validated rating scales to monitor patients with a diagnosis of major depression.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Implement regular use of validated rating scales and questionnaires to establish a baseline assessment to objectively measure the changes in clinical status over time of patients being treated for major depressive disorder to remission.
  • Proactively engage the patient in the development of a treatment strategy that includes discussion of cognition, remission, and treatment side effects, and document the plan for the patient.
  • Evaluate available efficacy evidence regarding the current and latest approved therapeutics for the treatment of MDD.

Financial Support

This activity is supported by an educational grant from Takeda Pharmaceuticals International, Inc., U.S. Region and Lundbeck.

Target Audience

Physicians and other healthcare professionals who treat individuals with major depressive disorder.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Creditâ„¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Post-tests, credit request forms, and activity evaluations must be completed online at (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Steffens has no disclosures to report.

Dr. Nemeroff has disclosed that he receives grants/research support from the National Institutes of Health (NIH). He serves as a consultant to Allergen, Inc.; Eli Lilly and Company; Lundbeck; Mitsubishi Tanabe Pharma Development America; Prismic Pharmaceuticals; SK Pharma; Roche; Shire Pharmaceuticals; Taisho Pharmaceutical Inc.; Takeda Pharmaceuticals North America, Inc.; and Xhale, Inc. He serves on the scientific advisory boards of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); CeNeRx BioPharma; National Alliance for Research on Schizophrenia and Depression (NARSAD); PharmaNeuroBoost; Xhale, Inc.; and Skyland Trail. He serves on the board of directors of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); GratitudeAmerica, Inc.; NovaDel Pharma, Inc. (2011); and Skyland Trail. He is a stockholder of AbbVie Inc,; Celgene Corporation; CeNeRx BioPharma; PharmaNeuroBoost; Reevax Pharmaceuticals LLC; Seattle Genetics, Inc.; and Xhale, Inc. His other financial income sources or equity of $10,000 or more include American Psychiatric Publishing; BioPharma; CeNeRx NovaDel Pharma, Inc.; Pharmaneuroboost; Revaax Pharmaceuticals LLC; and Xhale, Inc. He holds patents for the following: method and devices for transdermal delivery of lithium (US 6,375,990B1); method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2).

Tony Graham, MD (content/peer reviewer) has no disclosures to report.

Robert Kennedy (planning committee) has no disclosures to report.

Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.

Sandra Haas Binford, MAEd (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Unlabeled Use Disclosure

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

CME Outfitters, LLC, the faculty, and Takeda Pharmaceuticals International, Inc., U.S. Region and Lundbeck do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download